Santos Byanca Rossetti Moreira Dos, Santos Carlos Henrique Marques Dos, Santos Vitória Rossetti Moreira Dos, Torrez Claudia Yanina Garcia, Palomares-Junior Daniel
Department of Surgery, Regional Hospital Rosa Pedrossian, Campo Grande, MS, Brazil.
Medicine, Anhanguera-Uniderp University, Campo Grande, MS, Brazil.
Arq Bras Cir Dig. 2020 Nov 20;33(2):e1522. doi: 10.1590/0102-672020200002e1522. eCollection 2020.
Anti-TNF drugs are a fundamental part of the treatment of Crohn's disease (CD), so identifying factors related to loss of response is of great importance in clinical practice.
Identify potential factors related to loss of response to anti-TNF agents in Crohn's disease patients.
This is a prospective study of CD patients attending a specialized outpatient clinic using a specific form, including patients with more than one year of follow-up on anti-TNF (Infliximab, Adalimumab or Certolizumab pegol). The information obtained was tabulated and analyzed to identify possible reasons for the loss of response to anti-TNF agents; results were submitted to statistical analysis by chi-square teste considering significant p<0.05.
Sixty-four patients were included, most of them females (56.3%), predominant age group between 26 and 55 years, of whom 25 required optimization, 23 remained in remission with the usual dose and interval, and 16 required switch; most of those who needed switch had hematological problems such as anemia and/or had already undergone surgical treatment for CD.
Anemia and prior CD surgery have been linked to loss of anti-TNF response.
抗 TNF 药物是克罗恩病（CD）治疗的重要组成部分，因此在临床实践中识别与反应丧失相关的因素非常重要。
确定克罗恩病患者对抗 TNF 药物反应丧失的潜在因素。
这是一项对在专门门诊就诊的 CD 患者进行的前瞻性研究，采用特定表格，包括接受抗 TNF（英夫利昔单抗、阿达木单抗或赛妥珠单抗）治疗随访一年以上的患者。对所获信息进行列表和分析，以确定抗 TNF 药物反应丧失的可能原因；结果采用卡方检验进行统计分析，显著性水平为 p<0.05。
纳入 64 例患者，其中大多数为女性（56.3%），主要年龄组在 26 至 55 岁之间，其中 25 例需要优化治疗，23 例以常规剂量和间隔维持缓解，16 例需要换药；大多数需要换药的患者有血液学问题，如贫血和/或已接受过 CD 手术治疗。
贫血和既往 CD 手术与抗 TNF 反应丧失有关。
